Has Zahid Awan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $478 in general payments to Zahid Awan, MD across 26 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Zahid Awan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Zahid Awan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Zahid Awan, MD

Psychiatry · Reading, PANPI 1952301988

Payments from drug & device makers

$478in general payments, 2019–2025

Across 26 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$125
Lundbeck LLC$106
AbbVie$67
GSK$44
Takeda Pharmaceuticals U.S.A., Inc.$39
Alkermes, Inc.$38
plus $60 from 3 others

What the payments were for

Food & beverage$44894%
Education$306%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	7	$125
Lundbeck LLC	6	$106
AbbVie(2 entities)	3	$67
GSK	2	$44
Takeda Pharmaceuticals U.S.A., Inc.	2	$39
Alkermes, Inc.	2	$38
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$26
Sunovion Pharmaceuticals Inc.	2	$17
Johnson & Johnson	1	$16

How this compares

$478 in reported general payments places this provider in the 65th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$47,390

Medicare patients

Services billed

585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Quetiapine Fumarate	169	$2,563
Clozapine	36	$2,266
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	36	$2,130
Bupropion XlBupropion Hcl	49	$1,611
Duloxetine Hcl	72	$1,436
Sertraline Hcl	92	$965
Venlafaxine Hcl ErVenlafaxine Hcl	77	$918
Vilazodone Hcl	12	$905
Olanzapine	64	$746
Guanfacine Hcl	12	$699
Oxcarbazepine	27	$663
Clonazepam	63	$572
Bupropion Hcl SrBupropion Hcl	56	$568
Gabapentin	40	$514
Perphenazine	12	$512

Paid to pharmacies, not to this prescriber.

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Most prescribed under Part D

Other psychiatry in Reading